Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia

CD22 耐火材料(行星科学) 嵌合抗原受体 CD19 医学 淋巴细胞白血病 白血病 B细胞 急性淋巴细胞白血病 CD20 抗原 内科学 肿瘤科 免疫学 癌症研究 T细胞 生物 抗体 免疫系统 天体生物学
作者
Tingting Yang,Yetian Dong,Mingming Zhang,Jingjing Feng,Shan Fu,Pingnan Xiao,Ruimin Hong,Huijun Xu,Jiazhen Cui,Simao Huang,Guoqing Wei,Delin Kong,Jia Geng,Alex H. Chang,He Huang,Yongxian Hu
出处
期刊:Experimental hematology & oncology [BioMed Central]
卷期号:14 (1): 2-2 被引量:9
标识
DOI:10.1186/s40164-024-00593-5
摘要

BACKGROUND: Sequential CD19 and CD22 chimeric antigen receptor (CAR)-T cell therapy offers a promising approach to antigen-loss relapse in relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL); however, research in adults remains limited. METHODS: This study aimed to evaluate the efficacy and safety of sequential CD19 and CD22 CAR-T cell therapy in adult patients with R/R B-ALL between November 2020 and November 2023 (ChiCTR2100053871). Key endpoints included the adverse event incidence, overall survival (OS), and leukemia-free survival (LFS). RESULTS: Twenty-three patients with a median age of 58.1 years (range 25.9-75.0) were enrolled. High-risk cytogenetic and genomic aberrations were identified in 43.5% of patients, and five patients had baseline extramedullary disease (EMD). The median interval between the two infusions was 3.8 months. Grade ≥ 3 hematological adverse events occurred at comparable rates after both infusions. Cytokine release syndrome was observed in 78.3% and 39.1% of patients after CD19 and CD22 CAR-T therapy, respectively. Two patients experienced grade 2 immune effector cell-associated neurotoxicity syndrome (ICANS) during CD19 CAR-T, and no ICANS was reported during CD22 CAR-T. The median OS was not reached with a median follow-up of 19.4 months (range 8.7-45.6), while the median LFS was 20.8 months. OS and LFS rates were 91.3% and 67.1% at 1 year and 58.6% and 47.0% at 2 years, respectively. Eight patients experienced relapse, with the cumulative incidence of relapse being 28.6% at 1 year and 42.5% at 2 years. Higher baseline leukemia burden (≥ 64% bone marrow blasts) and the presence of EMD were significant risk factors for inferior OS and LFS, respectively. CONCLUSIONS: Sequential CAR-T cell therapy demonstrated durable efficacy and a manageable safety profile in R/R B-ALL, providing a viable option to address antigen-loss relapse and improve long-term outcomes in high-risk adult patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
水煮电吹风的应助被LioraY采纳,获得10
刚刚
刚刚
刚刚
刚刚
刚刚
1秒前
1秒前
1秒前
2秒前
米糊发布了新的文献求助10
2秒前
典雅胜完成签到,获得积分10
2秒前
3秒前
麦粑块发布了新的文献求助10
3秒前
王海鹏完成签到,获得积分10
4秒前
顺利的梦松完成签到 ,获得积分10
4秒前
4秒前
5秒前
5秒前
米糊发布了新的文献求助10
5秒前
Owen的应助被科研通管家采纳,获得10
5秒前
送我上青云完成签到,获得积分10
5秒前
米糊发布了新的文献求助10
5秒前
赘婿的应助被科研通管家采纳,获得10
5秒前
dianhuaxue发布了新的文献求助10
5秒前
脑洞疼的应助被科研通管家采纳,获得10
5秒前
搜集达人的应助被科研通管家采纳,获得10
5秒前
6秒前
小太阳发布了新的文献求助10
6秒前
完美世界的应助被科研通管家采纳,获得10
6秒前
6秒前
6秒前
酷波er的应助被科研通管家采纳,获得10
6秒前
桐桐的应助被科研通管家采纳,获得10
6秒前
llay发布了新的文献求助10
6秒前
大模型的应助被科研通管家采纳,获得10
6秒前
6秒前
领导范儿的应助被科研通管家采纳,获得10
6秒前
zjm完成签到,获得积分10
7秒前
Jasper的应助被科研通管家采纳,获得10
7秒前
慕青的应助被科研通管家采纳,获得10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183263
求助须知:如何正确求助?哪些是违规求助? 9572532
关于积分的说明 21826339
捐赠科研通 7780187
什么是DOI,文献DOI怎么找? 3433993
关于科研通互助平台的介绍 2558131
邀请新用户注册赠送积分活动 2480239